Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Amicus Therapeutics is a commercial-stage biotechnology company focused on rare genetic diseases, primarily Fabry disease. The company's lead product Galafold (migalastat) is an oral precision medicine approved in over 50 countries for treating amenable mutations of Fabry disease, competing against enzyme replacement therapies. With 90% gross margins and accelerating revenue growth (32% YoY), the company is transitioning from cash-burn to profitability as Galafold penetrates the estimated 3,000-5,000 amenable Fabry patient population globally.
Amicus generates revenue through direct commercial sales of Galafold in the US and Europe, plus partnership agreements in other territories. The oral precision medicine targets patients with amenable GLA mutations (30-50% of Fabry population), offering differentiated convenience versus IV enzyme replacement therapy. Pricing power is strong given orphan drug status, limited competition for amenable mutations, and chronic lifetime treatment requirement. The company benefits from high gross margins (90%) typical of specialty pharmaceuticals, with profitability dependent on scaling commercial infrastructure across the small but high-value rare disease patient base. Revenue growth is driven by new patient starts, geographic expansion, and potential label expansions.
Galafold quarterly revenue performance and new patient enrollment trends across US and EU markets
Clinical trial readouts and regulatory milestones for AT-GAA (Pompe disease gene therapy) program
Operating margin trajectory and path to sustained profitability with positive free cash flow
Label expansion opportunities for Galafold (pediatric indications, additional mutations)
Competitive dynamics with enzyme replacement therapies (Fabrazyme, Replagal) and emerging gene therapies
Gene therapy competition threatens long-term Galafold franchise - one-time curative treatments could displace chronic oral therapy, particularly as Fabry gene therapies advance through clinical development
Pricing pressure from global healthcare cost containment - orphan drugs face increasing scrutiny despite rare disease status, with potential reference pricing across geographies and mandatory discounts
Regulatory pathway complexity for rare diseases - small patient populations create statistical challenges for clinical trials, and label restrictions (amenable mutations only) limit addressable market to subset of Fabry patients
Established enzyme replacement therapies (Sanofi's Fabrazyme, Takeda's Replagal) retain majority market share with decades of real-world data and physician familiarity, despite IV administration burden
Emerging gene therapy competitors (4D Molecular, Freeline Therapeutics) could offer superior efficacy and one-time treatment paradigm, fundamentally disrupting chronic therapy model
Pompe disease pipeline (AT-GAA) faces entrenched competition from Sanofi's Lumizyme and emerging next-generation enzyme replacements with potentially superior profiles
Negative free cash flow (-$0.8% yield) and operating cash flow requires continued capital access - equity dilution risk if unable to achieve sustained profitability before cash reserves deplete
Elevated debt/equity ratio (1.92) increases financial leverage risk, particularly if revenue growth disappoints or pipeline programs require additional investment beyond current cash position
High valuation multiples (7.5x P/S, 80x EV/EBITDA) leave limited margin for execution missteps - any revenue miss or pipeline setback could trigger significant multiple compression
low - Rare disease treatments are medically necessary, chronic therapies with limited discretionary demand sensitivity. Fabry disease causes progressive organ damage requiring continuous treatment regardless of economic conditions. Payer coverage (government and private insurance) insulates revenue from GDP fluctuations. However, healthcare budget pressures during recessions could impact reimbursement negotiations and prior authorization timelines.
Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable biotech stocks trading on future earnings potential, particularly impacting the 7.5x P/S multiple; (2) Increased cost of capital affects pipeline investment decisions and potential M&A activity. The company's 1.92 debt/equity ratio means financing costs impact cash burn, though operating cash flow is approaching breakeven. Lower rates historically correlate with biotech sector outperformance and higher risk appetite for growth stories.
Moderate exposure through two mechanisms: Tighter credit conditions reduce access to capital markets for future financing needs (company still cash flow negative with -$0.8% FCF yield), potentially forcing dilutive equity raises. Additionally, stressed healthcare payers may delay reimbursement or tighten prior authorizations during credit crunches, though orphan drug status provides some insulation. The 2.99 current ratio provides near-term liquidity buffer.
growth - The 93.5% six-month return and 32% revenue growth attract momentum and growth investors focused on commercial-stage biotech inflection stories. The company appeals to specialized healthcare investors seeking exposure to rare disease franchises with high barriers to entry and pricing power. Recent positive operating margin achievement attracts crossover investors looking for transition from cash-burn to profitability. High volatility and negative free cash flow deter value and income investors, while the pipeline optionality (Pompe gene therapy) attracts biotech specialists willing to underwrite binary clinical outcomes.
high - Biotechnology stocks exhibit elevated volatility driven by binary clinical/regulatory events, and small-cap biotech ($4.5B market cap) amplifies this. The 49.5% three-month return demonstrates momentum-driven price action. Stock sensitivity to pipeline updates, quarterly revenue beats/misses, and sector rotation creates significant intra-quarter volatility. Limited analyst coverage and institutional ownership in commercial-stage rare disease names increases susceptibility to technical trading patterns and sector-wide risk-on/risk-off flows.
